Janus Henderson Group PLC bought a new position in Dianthus Therapeutics, Inc. (NASDAQ:DNTH – Free Report) in the first quarter, according to the company in its most recent disclosure with the SEC. The fund bought 375,044 shares of the company’s stock, valued at approximately $11,251,000. Janus Henderson Group PLC owned 1.28% of Dianthus Therapeutics at the end of the most recent quarter.
A number of other hedge funds have also added to or reduced their stakes in the stock. Tower Research Capital LLC TRC purchased a new stake in shares of Dianthus Therapeutics in the 4th quarter worth $25,000. Hussman Strategic Advisors Inc. bought a new position in shares of Dianthus Therapeutics in the first quarter worth about $630,000. StemPoint Capital LP purchased a new position in shares of Dianthus Therapeutics during the 1st quarter valued at about $1,304,000. Octagon Capital Advisors LP grew its stake in shares of Dianthus Therapeutics by 15.4% during the 4th quarter. Octagon Capital Advisors LP now owns 554,000 shares of the company’s stock valued at $5,762,000 after acquiring an additional 74,000 shares during the period. Finally, Vestal Point Capital LP purchased a new stake in Dianthus Therapeutics in the 4th quarter worth approximately $1,404,000. 47.53% of the stock is currently owned by hedge funds and other institutional investors.
Dianthus Therapeutics Trading Down 5.9 %
Shares of Dianthus Therapeutics stock opened at $28.01 on Friday. The stock has a 50 day moving average price of $25.56 and a 200-day moving average price of $24.36. Dianthus Therapeutics, Inc. has a one year low of $6.58 and a one year high of $33.77.
Wall Street Analyst Weigh In
Several equities analysts have recently commented on the company. Wedbush boosted their price objective on Dianthus Therapeutics from $33.00 to $38.00 and gave the company an “outperform” rating in a research report on Friday, May 10th. Lifesci Capital raised shares of Dianthus Therapeutics to a “strong-buy” rating in a report on Tuesday, June 11th. Robert W. Baird assumed coverage on shares of Dianthus Therapeutics in a report on Friday, July 26th. They issued an “outperform” rating and a $58.00 target price on the stock. HC Wainwright started coverage on shares of Dianthus Therapeutics in a research note on Thursday, May 16th. They set a “buy” rating and a $40.00 target price for the company. Finally, Baird R W upgraded shares of Dianthus Therapeutics to a “strong-buy” rating in a report on Friday, July 26th. Eight research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Buy” and an average target price of $45.00.
Check Out Our Latest Report on DNTH
About Dianthus Therapeutics
Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.
Featured Articles
- Five stocks we like better than Dianthus Therapeutics
- 2 Fintech Stocks to Buy Now and 1 to Avoid
- Investors Flock to Auto Retail Stock as It Hits New Highs
- There Are Different Types of Stock To Invest In
- Take a Bite: This Snack Giant Is a Safe-Haven Stock Worth Buying
- How to Use the MarketBeat Excel Dividend Calculator
- EA’s New Game Launch Boosts Stock: Is It Time to Buy?
Want to see what other hedge funds are holding DNTH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Dianthus Therapeutics, Inc. (NASDAQ:DNTH – Free Report).
Receive News & Ratings for Dianthus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dianthus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.